-
公开(公告)号：US09173883B2
公开(公告)日：2015-11-03
申请号：US14402541
申请日：2013-05-20
Applicant: Novartis AG
Inventor： Matthew Burger , Joseph E. Drumm, III , Gisele Nishiguchi , Alice Rico , Robert Lowell Simmons , Benjamin Taft , Huw Tanner
IPC: C07D403/12 , C07D401/14 , C07D401/12 , C07D403/14 , C07D407/14 , C07D409/14 , C07D417/12 , C07D417/14 , C07D213/81 , C07D405/14 , A61K31/506 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/675 , A61K45/06 , C07F9/6558
CPC classification number: A61K31/506 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/675 , A61K45/06 , C07D213/81 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D407/14 , C07D409/14 , C07D417/12 , C07D417/14 , C07F9/65583
Abstract: The present invention provides a compound of formula (A): as described herein, and pharmaceutically acceptable salts, enantiomers, rotamers, tautomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by PIM kinase using the compounds of Formula I, and pharmaceutical compositions comprising such compounds.
Abstract translation: 本发明提供式（A）化合物：如本文所述，及其药学上可接受的盐，对映异构体，旋转异构体，互变异构体或外消旋体。 还提供了使用式I化合物治疗PIM激酶介导的疾病或病症的方法和包含这些化合物的药物组合物。
-
公开(公告)号：US20150133473A1
公开(公告)日：2015-05-14
申请号：US14402541
申请日：2013-05-20
Applicant: NOVARTIS AG
Inventor： Matthew Burger , Joseph E. Drumm III , Gisele Nishiguchi , Alice Rico , Robert Lowell Simmons , Benjamin Taft , Huw Tanner
IPC: C07D417/14 , C07D417/12 , C07D409/14 , C07D405/14 , C07D401/14 , C07D401/12
CPC classification number: A61K31/506 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/675 , A61K45/06 , C07D213/81 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D407/14 , C07D409/14 , C07D417/12 , C07D417/14 , C07F9/65583
Abstract: The present invention provides a compound of formula (A): as described herein, and pharmaceutically acceptable salts, enantiomers, rotamers, tautomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by PIM kinase using the compounds of Formula I, and pharmaceutical compositions comprising such compounds.
-
Patent Agency Ranking
公开(公告)号：US09242969B2
公开(公告)日：2016-01-26
申请号：US14204823
申请日：2014-03-11
Applicant: Novartis AG
Inventor： Paul A. Barsanti , Matthew Burger , Yan Lou , Gisele Nishiguchi , Valery Polyakov , Savithri Ramurthy , Alice Rico , Lina Setti , Aaron Smith , Benjamin Taft , Huw Tanner , Alan DiPesa , Naeem Yusuff
IPC: C07D401/04 , C07D403/04 , A61K31/5377 , A61K31/541 , C07D413/04 , A61K45/06 , C07D213/74 , C07D237/20 , C07D239/42 , C07D239/47 , C07D239/48 , C07D277/42 , C07D401/12 , C07D413/12 , C07D413/14 , C07D417/12 , C07D493/10 , C07D403/12 , C07D401/14 , C07D405/14 , C07D213/75 , C07D233/88 , C07D405/04 , C07D405/12 , C07D241/20 , C07D471/04 , C07D487/04 , C07D263/58 , C07D491/107 , C07D493/04 , C07D495/04 , C07D498/08 , C07D513/04
CPC classification number: A61K31/5377 , A61K31/444 , A61K31/501 , A61K31/5375 , A61K31/541 , A61K45/06 , C07B59/002 , C07B2200/05 , C07D213/74 , C07D213/75 , C07D213/81 , C07D213/82 , C07D213/84 , C07D233/88 , C07D237/20 , C07D237/22 , C07D237/24 , C07D239/42 , C07D239/47 , C07D239/48 , C07D241/20 , C07D263/58 , C07D277/42 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D405/04 , C07D405/12 , C07D405/14 , C07D409/14 , C07D413/04 , C07D413/12 , C07D413/14 , C07D417/12 , C07D471/04 , C07D487/04 , C07D491/04 , C07D491/048 , C07D491/08 , C07D491/107 , C07D493/04 , C07D493/10 , C07D495/04 , C07D498/08 , C07D513/04
Abstract: The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.
Abstract translation: 本发明提供了本文所述的式（I）化合物及其盐，以及这些化合物治疗与Raf激酶活性相关的疾病的治疗用途。 本发明还提供包含这些化合物的药物组合物，以及包含这些化合物和治疗性助剂的组合物。
-
公开(公告)号：US08987457B2
公开(公告)日：2015-03-24
申请号：US13897927
申请日：2013-05-20
Applicant: Novartis AG
Inventor： Matthew Burger , Joseph E. Drumm, III , Gisele Nishiguchi , Alice Rico , Robert Lowell Simmons , Benjamin Taft , Huw Tanner
IPC: C07D211/68 , C07D213/44 , C07D417/00 , A61K31/445 , A61K31/41 , C07D213/81 , C07D403/12 , C07D401/14 , C07D401/12 , C07D403/14 , C07D407/14 , C07D409/14 , C07D417/12 , C07D417/14 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/506 , A61K31/675 , A61K45/06 , C07D405/14 , C07F9/6558
CPC classification number: A61K31/506 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/675 , A61K45/06 , C07D213/81 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D407/14 , C07D409/14 , C07D417/12 , C07D417/14 , C07F9/65583
Abstract: The present invention provides a compound of formula (A): as described herein, and pharmaceutically acceptable salts, enantiomers, rotamers, tautomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by PIM kinase using the compounds of Formula I, and pharmaceutical compositions comprising such compounds.
-
公开(公告)号：US20150150873A1
公开(公告)日：2015-06-04
申请号：US14620649
申请日：2015-02-12
Applicant: Novartis AG
Inventor： Matthew Burger , Joseph E. Drumm III , Gisele Nishiguchi , Alice Rico , Robert Lowell Simmons , Benjamin Taft , Huw Tanner
IPC: A61K31/506 , A61K31/4545 , A61K31/4439 , A61K31/444
CPC classification number: A61K31/506 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/675 , A61K45/06 , C07D213/81 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D407/14 , C07D409/14 , C07D417/12 , C07D417/14 , C07F9/65583
Abstract: The present invention provides a compound of formula (A): as described herein, and pharmaceutically acceptable salts, enantiomers, rotamers, tautomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by PIM kinase using the compounds of Formula I, and pharmaceutical compositions comprising such compounds.
Abstract translation: 本发明提供式（A）化合物：如本文所述，及其药学上可接受的盐，对映异构体，旋转异构体，互变异构体或外消旋体。 还提供了使用式I化合物治疗PIM激酶介导的疾病或病症的方法和包含这些化合物的药物组合物。
-
公开(公告)号：US09694016B2
公开(公告)日：2017-07-04
申请号：US14774431
申请日：2014-03-13
Applicant: Novartis AG
Inventor： Robert John Aversa , Paul Andrew Barsanti , Matthew Burger , Michael Patrick Dillon , Alan Dipesa , Cheng Hu , Yan Lou , Gisele Nishiguchi , Yue Pan , Valery Polyakov , Savithri Ramurthy , Alice Rico , Lina Setti , Aaron Smith , Sharadha Subramanian , Benjamin Taft , Huw Tanner , Lifeng Wan , Naeem Yusuff
IPC: C07D413/14 , C07D403/14 , C07D403/12 , C07D401/04 , A61K31/5377 , C07D413/04 , A61K31/541 , A61K45/06 , C07D213/74 , C07D237/20 , C07D239/42 , C07D239/47 , C07D239/48 , C07D277/42 , C07D401/12 , C07D403/04 , C07D413/12 , C07D417/12 , C07D493/10 , C07D401/14 , C07D405/14 , C07D213/75 , C07D233/88 , C07D405/04 , C07D405/12 , C07D241/20 , C07D471/04 , C07D487/04 , C07D263/58 , C07D491/107 , C07D493/04 , C07D495/04 , C07D498/08 , C07D513/04 , A61K31/5375 , C07D213/81 , C07D213/82 , C07D213/84 , C07D237/22 , C07D409/14 , C07D491/048
CPC classification number: A61K31/5377 , A61K31/444 , A61K31/501 , A61K31/5375 , A61K31/541 , A61K45/06 , C07B59/002 , C07B2200/05 , C07D213/74 , C07D213/75 , C07D213/81 , C07D213/82 , C07D213/84 , C07D233/88 , C07D237/20 , C07D237/22 , C07D237/24 , C07D239/42 , C07D239/47 , C07D239/48 , C07D241/20 , C07D263/58 , C07D277/42 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D405/04 , C07D405/12 , C07D405/14 , C07D409/14 , C07D413/04 , C07D413/12 , C07D413/14 , C07D417/12 , C07D471/04 , C07D487/04 , C07D491/04 , C07D491/048 , C07D491/08 , C07D491/107 , C07D493/04 , C07D493/10 , C07D495/04 , C07D498/08 , C07D513/04
Abstract: The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.
-
公开(公告)号：US20130336965A1
公开(公告)日：2013-12-19
申请号：US13897927
申请日：2013-05-20
Applicant: Novartis AG
Inventor： Matthew Burger , Joseph E. Drumm, III , Gisele Nishiguchi , Alice Rico , Robert Lowell Simmons , Benjamin Taft , Huw Tanner
IPC: C07D213/81 , A61K31/506 , A61K31/4545 , A61K31/444 , A61K31/4439 , A61K45/06 , C07D405/14 , C07F9/6558 , C07D401/14 , C07D417/12 , C07D409/14 , C07D417/14 , A61K31/675 , C07D401/12
CPC classification number: A61K31/506 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/675 , A61K45/06 , C07D213/81 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D407/14 , C07D409/14 , C07D417/12 , C07D417/14 , C07F9/65583
Abstract: The present invention provides a compound of formula (A): as described herein, and pharmaceutically acceptable salts, enantiomers, rotamers, tautomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by PIM kinase using the compounds of Formula I, and pharmaceutical compositions comprising such compounds.
-
-
-
-
-
-
Search Results
7
records
(took 0.041 seconds)
